Replies to post #2132 on SurModics Inc (SRDX)

[DewDiligence]

OctoPlus to Conduct Drug-Delivery Feasibility Study for Unnamed US-Based Biotech

http://biz.yahoo.com/iw/081112/0451652.html

›Wednesday November 12, 2:18 am ET

LEIDEN, NETHERLANDS--(MARKET WIRE)--Nov 12, 2008 -- As part of the Company's recently announced strategic focus on developing controlled release formulations for clients, OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces today that it has signed a new drug delivery technology evaluation contract with a US-based biotech company.

On 6 October, OctoPlus announced a licensing agreement with Biolex Therapeutics, to license Locteron®, a product based on OctoPlus' PolyActive® drug delivery technology, to Biolex. OctoPlus' strategy will increasingly focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. Currently, OctoPlus is working on five projects to develop a controlled release formulation for a client.

Under the contract announced today, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus' proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.‹

[DewDiligence]

SRDX has a 4.9% equity stake in OctoPlus:

http://finance.yahoo.com/news/OctoPlus-Gives-Update-on-iw-14549396.html

[Democritus_of_Abdera]

Octoplus Readme First Update

Updated to include the phase 2b results for Locteron as well as some other minor additions.

See also: http://www.octoplus.nl (Euronext: OCTO), maintain a depressed “alt” key to load some pages

Surmodics’ Investment in OctoPlus (Euronext: OCTO)

#msg-12959885 (08/28/06): Introduction of OCTO to the SRDX message board

#msg-36064824 (03/05/09): SRDX’s 4.9% equity stake in OCTO (see also: #msg-13841250, #msg-12958080, #msg-33436621, #msg-13816009)

#msg-17141398 (02/16/07): Listing of biodegradable polymers purchased by SRDX from OCTO (see also: #msg-12262367)

Locteron & OctoPlus’ Collaboration with Biolex

Locteron, controlled release interferon alpha 2b, provides a once-every-two weeks dosing schedule reducing side effects, including flu-like symptoms, associated with pegylated interferons, the standard of care in treatment of hepatitis C.

#msg-36969497 (04/12/09): Locteron is placed in the third category on Dew’s list of HCV drugs most likely to succeed.

#msg-32924615 (10/06/08): OCTO’s agreement with Biolex regarding Locteron. Locteron combines OCTOs PolyActive® drug delivery technology with BLX-883, a recombinant alfa interferon produced by Biolex Therapeutics using transgenic-plant technology. (see also #msg-32662307; #msg-32662762, #msg-30621154)

#msg-15116312 (11/28/06): Description of Biolex’s technological advantages (see also: #msg-26942561, #msg-25179852, #msg-25183120)
#msg-21638503 (07/28/07): relationship between HGSI’s Albuferon and Locteron (see also: #msg-21637496, #msg-24371607, #msg-18342282)

#msg-37298340 (04/25/09): Phase-2a results for Locteron presented to the European Assoc for the Study of the Liver on April 24, 2009. (see also: #msg-28786162, #msg-26612906, #msg-23627540, #msg-24304055, #msg-21566438, #msg-16610930)

#msg-30621180 (07/11/08): Dew’s list of posts regarding Biolex

#msg-37178496 (04/20/09): Biolex commences phase-2b for Locteron in HCV to select dosages for phase-3 trials based on 12-wk data..

OctoPlus Products

#msg-18341699 (03/30/07): OCTO’s pipeline (see also: #msg-33503162).

#msg-19093576 (04/25/07): OCTOs acquisition of PolyActive drug delivery technology from IsoTis (see also #msg-19095262)

#msg-23219029 (09/27/07): OCTOs license of a GLP-1 agonist.

OctoPlus Reports

#msg-13828644 (10/06/06): Bridge posts a link to the OCTO prospectus.

#msg-17079056 (02/15/07): Dew summarizes OCTO 2006 results (see also: #msg-18338843)

#msg-21785811 (08/03/07): Dew posts OCTOs 1H07 results.

#msg-27020385 (02/22/08): Dew posts OCTOs 2H07 results.